Page last updated: 2024-12-05

nizofenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nizofenone: protects experimental mice & rats against cerebral anoxia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4514
CHEMBL ID2106822
CHEBI ID135668
SCHEMBL ID855561
MeSH IDM0067249

Synonyms (37)

Synonym
OPREA1_229738
93929-95-4
2'-chloro-2-(2-((diethylamino)methyl)imidazol-1-yl)-5-nitrobenzophenone
nizofenonum [inn-latin]
nizofenone
nizofenone [inn]
2'-chlor-2-(2-(diethylaminomethyl)-1-imidazolyl)-5-nitrobenzophenon
y 9179
nizofenona [inn-spanish]
CHEBI:135668
D08280
nizofenone (inn)
54533-85-6
FT-0658769
(2-chlorophenyl)-[2-[2-(diethylaminomethyl)imidazol-1-yl]-5-nitrophenyl]methanone
NCGC00183104-01
A830228
(2-chlorophenyl)-[2-[2-(diethylaminomethyl)imidazol-1-yl]-5-nitro-phenyl]methanone;nizofenone
CHEMBL2106822
nizofenona
unii-7a2noc3r88
7a2noc3r88 ,
nizofenonum
AKOS015909167
nizofenone [mart.]
nizofenone [jan]
nizofenone [mi]
nizofenone [who-dd]
SCHEMBL855561
(2-chlorophenyl)(2-(2-((diethylamino)methyl)-1h-imidazol-1-yl)-5-nitrophenyl)methanone
AC-1324
DB13546
Q15409362
DTXSID401014745
CS-0068612
HY-119513
AKOS040749029

Research Excerpts

Overview

Nizofenone is a potent neuroprotective drug which ameliorates this imbalance. Ischemia-induced excessive glutamate release has been completely blocked by this drug.

ExcerptReferenceRelevance
"Nizofenone is a potent neuroprotective drug which ameliorates this imbalance and also various pathophysiologic events during ischemia, such as ATP depletion, lactate accumulation, glutamate release, free fatty acid liberation, edema, and neuronal degeneration; in particular, ischemia-induced excessive glutamate release has been completely blocked by this drug."( Brain protection against ischemic injury by nizofenone.
Nakajima, A; Yasuda, H, 1993
)
1.27

Treatment

Pretreatment with nizofenone (3 and 10 mg/kg, i.v.) markedly increased the amount of ouabain needed to cause cardiac toxicity in pentobarbital-anesthetized dogs. Treatment was significantly more effective (p less than 0.05) than that with placebo.

ExcerptReferenceRelevance
"Pretreatment with nizofenone (3 and 10 mg/kg, i.v.) markedly increased the amount of ouabain needed to cause cardiac toxicity in pentobarbital-anesthetized dogs, to the same degree as quinidine (10 mg/kg, i.v.)."( [Effects of nizofenone on experimental arrhythmia in dogs].
Nakamura, T; Tsumagari, T, 1984
)
0.97
"Treatment with nizofenone was significantly more effective (p less than 0.05) than that with placebo based on functional recovery and other clinical findings."( Nizofenone administration in the acute stage following subarachnoid hemorrhage. Results of a multi-center controlled double-blind clinical study.
Hashi, K; Kikuchi, H; Kudo, Y; Ohta, T, 1986
)
2.05

Dosage Studied

ExcerptRelevanceReference
" The effective dosage of the drugs were 20-40 mg/kg in pentobarbital, 10-20 mg/kg in diazepam, and 12."( [Treatable ischemic neuronal damage in the gerbil hippocampus].
Kirino, T; Sano, K; Tamura, A; Tomukai, N, 1986
)
0.27
" And the degree of recovery of EEG was better in the group administered a large dosage than in those given a low dosage."( [An experimental study on the protective effect of nizofenone in cerebral ischemia].
Abiko, H; Fujimoto, S; Mizoi, K; Olca, M; Suzuki, J, 1984
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzophenonesAny aromatic ketone in which the carbonyl group is bonded to 2 phenyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (76.92)18.7374
1990's5 (19.23)18.2507
2000's0 (0.00)29.6817
2010's1 (3.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.87 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.90%)5.53%
Reviews2 (6.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (86.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]